{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"7.5","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Abemaciclib"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least one dose of study drug. Censored participants: Abemaciclib=35.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 27 Months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}